Literature DB >> 25048599

Elevated receptor for activated C kinase 1 expression is involved in intracellular Ca2+ influx and potentially associated with compromised regulatory T cell function in patients with asthma.

T Negoro1, S Shimizu, M Narushima, A H Banham, H Wakabayashi, R Takayanagi, T Hagiwara, G Roncador, T Osabe, T Yanai, M Kin, K Ikeda, A Endo, H Akiyama, Y Nakano.   

Abstract

BACKGROUND: Regulatory T cells (T(regs)) are activated during anergy in response to T cell receptor (TCR) activation and functional immune suppression. Anergy of paediatric T(regs) is partially dependent on intracellular calcium mobility; following TCR activation, T(regs) do not exhibit increased intracellular Ca(2+) concentration ([Ca(2+) ](i)).
OBJECTIVE: We determined whether [Ca(2+) ](i) in adult T(regs) defined their anergy, if intracellular Ca(2+) movement was linked to regulatory functions, whether [Ca(2+)](i) was indicative of asthma pathology, and the potential molecular mechanism responsible for Ca(2+) movement in T(regs).
METHODS: T(regs) were purified by the magnetic bead method, and their regulatory functions were assessed by monitoring carboxyfluorescein succinimidyl ester-labelled responder T cell proliferation. The Ca(2+) response of Fura-2-labelled cells was measured using a video image analysis system. To analyse the functions of T(regs) at the molecular level, we generated Jurkat Tet-On(®) clones with doxycycline (Dox)-induced forkhead box P3 (FOXP3) protein expression.
RESULTS: CD4(+) CD25(+) CD127(-/low) T(regs) from participants without asthma did not elicit Ca(2+) influx in response to TCR activation, exhibited little proliferation and suppressed proliferation of CD4(+) CD25(-) T cells. In contrast, under similar conditions, T(regs) from patients with asthma exhibited increased [Ca(2+)](i) and robust proliferation with partial loss of regulatory functions. FOXP3 protein levels in Tet-On(®) clones were high after both 2- and 5-day Dox treatment; however, 5-day cells were comparable with T(regs) from patients with asthma, whereas 2-day cells were similar to T(regs) from participants without asthma. Increasing [Ca(2+)](i) induced a high level of receptor for activated C kinase 1 (RACK1) expression in 5-day cells. CONCLUSIONS AND CLINICAL RELEVANCE: We confirmed that T(regs) in patients with asthma are functionally impaired and that the abnormal regulatory functions of these cells can be analysed by [Ca(2+)](i) following TCR engagement. Furthermore, the impaired functioning of T(regs) evident in patients with asthma may be due to a high level of RACK1.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  FOXP3; RACK1; asthma; calcium; regulatory T cell

Mesh:

Substances:

Year:  2014        PMID: 25048599     DOI: 10.1111/cea.12375

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  4 in total

1.  RACK1 plays a critical role in mast cell secretion and Ca2+ mobilization by modulating F-actin dynamics.

Authors:  Edismauro G Freitas Filho; Elaine Z M da Silva; Hwei Ling Ong; William D Swaim; Indu S Ambudkar; Constance Oliver; Maria Célia Jamur
Journal:  J Cell Sci       Date:  2021-05-13       Impact factor: 5.285

2.  Impaired Autophagy and Defective T Cell Homeostasis in Mice with T Cell-Specific Deletion of Receptor for Activated C Kinase 1.

Authors:  Guihua Qiu; Jian Liu; Qianqian Cheng; Qingyang Wang; Zhaofei Jing; Yujun Pei; Min Zhao; Jing Wang; Jessie Yanxiang Guo; Jiyan Zhang
Journal:  Front Immunol       Date:  2017-05-18       Impact factor: 7.561

3.  Surface Phenotype Changes and Increased Response to Oxidative Stress in CD4+CD25high T Cells.

Authors:  Yoshiki Yamamoto; Takaharu Negoro; Rui Tada; Michiaki Narushima; Akane Hoshi; Yoichi Negishi; Yasuko Nakano
Journal:  Biomedicines       Date:  2021-05-29

4.  Dual role of RACK1 in airway epithelial mesenchymal transition and apoptosis.

Authors:  Yue Pu; Yuan-Qi Liu; Yan Zhou; Yi-Fan Qi; Shi-Ping Liao; Shi-Kun Miao; Li-Ming Zhou; Li-Hong Wan
Journal:  J Cell Mol Med       Date:  2020-02-17       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.